Dr. Nagender Sharma
Principal Consultant
Medical Oncology, Cancer Care / Oncology, Head & Neck Oncology, Thoracic Oncology, Gastrointestinal & Hepatobiliary Oncology, Uro-Oncology, Gynecologic Oncology, Breast Cancer
Max Super Speciality Hospital, Saket
Max Hospital, Gurgaon
Max Smart Super Speciality Hospital, Saket
Experience: 6+ Years
Share Doctor Profile
Select Hospital
About Dr. Nagender Sharma
Work Experience
- Consultant, Department of Medical Oncology & Hematology, Medanta The Medicity, Gurugram, Feb 2020 to Aug 2022
- Associate Consultant, Department of Medical Oncology & Hematology, Medanta The Medicity, Gurugram, 2017-2020
- DNB, Medical Oncology (Secondary), National Board of Examination, New Delhi, 2017
- DM, Cancer Institute (WIA), Adyar, Chennai (Tamil Nadu), 2013-2017
- Senior Resident, Medical Oncology & Hematology, Medanta The Medicity, Gurugram, 2012-2013
Education & Training
- MBBS, Kasturba Medical College, Mangalore (Karnataka)
- MD - Medicine, M. R. Medical College, Gulbarga (Karnataka)
- DM - Medical Oncology, Cancer Institute (WIA), Adyar, Chennai, Tamil Nadu)
- DNB - Medical Oncology, National Board of Examination, New Delhi
- Ex-Assistant Professor of Internal Medicine, MAMC, Agroha, Hisar
- ESMO (European Society of Medical Oncology Certification (Europe)
Memberships
- Indian Society of Medical & Paediatric Oncology (ISMPO)
- Indian Cooperative Oncology Network (ICON)
- European Society for Medical Oncology (ESMO)
- Member of American Society of Clinical Oncology (ASCO)
Speciality Interest
- Thoracic & Breast Malignancy
- Sarcomas
- Gastrointestinal, Genitourinary Gynecology
- Head & Neck Malignancy
- Cancer Immunotherapy, Hormonal Therapy, Targeted Therapies & Cancer Vaccination
- Carcinomas of Unknown Primaries & Rare Malignancy
Research Papers & Publications
- Co-Principal Investigator in TALAPRO-III Phase-III International Multicenter Study
- TALAPRO-3, A Phase III Randomised, Double Blind, Study of Talazoparib with Enzalutamide Versus Placebo with Enzalutamide in Men with DDR Gene Mutated Metastatic Castration Sensitive Prostate Cancer
- Paralysis of Diaphragm after SBRT of Lung Cancer (J Radiosurgery)
- Subclinical Hyperthyroidism in post Immunotherapy Lung Cancer on FFDG PET/CT-An Incidental Observation (IJC)
- Ecacy and Safety of Palbociclib in Treatment of HR-positive Advanced Breast Cancer Patients: A Single Center Real-world Experience (JCO)
- Survival Outcomes in Patients with Metastatic Breast Cancer Treated with Eribulin: A Real-world Evidence Study from India (JCO)
OPD Timings
- Mon - 9:00 to 12:30
- Tue - 12:30 to 4:00
- Wed - 9:00 to 12:30
- Thu - 9:00 to 12:30
- Fri - 12:30 to 4:00
- Sat - 12:30 to 4:00